NEOPATH TARGETING AUTOPAP 300 QC CERVICAL CYTOLOGY READER TO 5-6 LARGEST LABS; FDA APPROVAL OF FIRST AUTOMATED PAP SMEAR ANALYZER TAKES SEVEN MONTHS
This article was originally published in The Gray Sheet
Executive Summary
NeoPath's AutoPap 300 QC automated cervical cytology reader sped to approval after an FDA review of seven months, becoming the first device of its kind to reach the U.S. market following FDA sign-off on Sept. 29.